{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00029189", "CSN": null, "TRF": "ORD_1623178_01", "MRN": "49225287", "PhysicianId": "109266", "NPI": null}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1316198", "clinicalId": "1317545", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1623178_01", "SampleName": "US1548766.01", "Version": "0", "Sample": {"FM_Id": "ORD_1623178_01", "SampleId": "US1548766.01", "BlockId": "nan", "TRFNumber": "ORD_1623178_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2023_05_04", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "38", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10104", "MRN": "49225287", "FullName": "\u738b\u5efa\u767c", "FirstName": "Chien_Fa", "LastName": "Wang", "SubmittedDiagnosis": "Esophagus cancer (NOS)", "Gender": "Male", "DOB": "1958_10_05", "OrderingMD": "\u9673\u660e\u6643", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2023_05_01", "ReceivedDate": "2023-05-15 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Esophageal Cancer"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "31", "clinicalTrialCount": "16", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "ATR", "isVUS": "true", "variantName": "Y1651D"}, {"geneName": "BRCA2", "isVUS": "true", "variantName": "G2508S"}, {"geneName": "CBFB", "isVUS": "true", "variantName": "amplification"}, {"geneName": "CD22", "isVUS": "true", "variantName": "amplification"}, {"geneName": "FGFR2", "isVUS": "true", "variantName": "V463D"}, {"geneName": "FOXL2", "isVUS": "true", "variantName": "G342S"}, {"geneName": "GABRA6", "isVUS": "true", "variantName": "R84H"}, {"geneName": "GATA4", "isVUS": "true", "variantName": "P161R"}, {"geneName": "KLHL6", "isVUS": "true", "variantName": "W412*"}, {"geneName": "MAP3K1", "isVUS": "true", "variantName": "A122S"}, {"geneName": "PIK3C2G", "isVUS": "true", "variantName": "P880T"}, {"geneName": "PIK3CB", "isVUS": "true", "variantName": "M555S"}, {"geneName": "PIK3R1", "isVUS": "true", "variantName": "Y452C"}, {"geneName": "PTEN", "isVUS": "true", "variantName": "K128S"}, {"geneName": "RAD52", "isVUS": "true", "variantName": "amplification"}, {"geneName": "REL", "isVUS": "true", "variantName": "M603K"}, {"geneName": "ROS1", "isVUS": "true", "variantName": "D2213E"}, {"geneName": "SGK1", "isVUS": "true", "variantName": "amplification"}, {"geneName": "TNFRSF14", "isVUS": "true", "variantName": "amplification"}, {"geneName": "TP53", "isVUS": "true", "variantName": "G356R"}, {"geneName": "TYRO3", "isVUS": "true", "variantName": "K388N"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "CCND2", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "CCND2 encodes the protein cyclin D2, which binds and regulates the cyclin_dependent kinases that control cell cycle progression, and is a downstream target of cancer signaling pathways including hedgehog and PI3K (Katoh and Katoh, 2009; 19860666, White et al., 2006; 16301994). CCND2 has been reported to be amplified in cancer (Gao et al., 2013; 23550210), and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). Putative high_level amplification of CCND2 has been reported in 2% of gastric carcinomas and in 1% of esophageal carcinomas, whereas CCND2 mutation has only been reported in 0.5% of esophageal carcinomas (Cancer Genome Atlas Research Network., 2017; 28052061). Published data investigating the prognostic implications of CCND2 alterations in esophageal carcinoma are limited (PubMed, Nov 2022). Although preclinical studies suggest that cyclin D2 activates CDK4/6 (Busk et al., 2005; 15707582, Busk, 2003; 12695654), it is unknown whether CCND2 amplification or activating mutation predicts response to CDK4/6 inhibitors such as abemaciclib, palbociclib, and ribociclib. Clinical studies of CDK4/6 inhibitors have shown the most promise for estrogen receptor_positive breast cancer (Finn et al., 2014; 25524798, DeMichele et al., 2014; 25501126).", "Include": "true", "ClinicalTrialNote": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04282031", "Include": "true"}, {"nctId": "NCT03994796", "Include": "true"}, {"nctId": "NCT05252416", "Include": "true"}, {"nctId": "NCT02896335", "Include": "true"}, {"nctId": "NCT05159245", "Include": "true"}, {"nctId": "NCT03310879", "Include": "true"}, {"nctId": "NCT03454035", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "PTEN", "Include": "true", "Alterations": {"Alteration": {"Name": "C218*", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "0.82", "isEquivocal": "false", "name": "C218*"}}, "Interpretation": "PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K_AKT_mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis (Simpson and Parsons, 2001; 11237521). Alterations such as seen here may disrupt PTEN function or expression (Campbell et al., 2003; 12857747, Rodr\u00edguez_Escudero et al., 2011; 21828076, He et al., 2013; 23475934, Han et al., 2000; 10866302, Myers et al., 1998; 9811831, Pradella et al., 2014; 24498881, Kim et al., 2011; 21536651, Denning et al., 2007; 17213812, Hlobilkova et al., 2006; 16619501, Redfern et al., 2010; 20718038, Shenoy et al., 2012; 22505997, Wang et al., 2009; 19329485, Okumura et al., 2006; 16829519, Lee et al., 1999; 10555148, Maxwell et al., 1998; 9635567, Risinger et al., 1998; 9865913, Kato et al., 2000; 11051241, Fenton et al, 2012; 22891331, Ngeow et al., 2012; 23066114, Lobo et al., 2009; 19457929, Liu et al., 2014; 23995781, Maehama et al., 2001; 11395408, De Vivo et al., 2000; 10807691, Ramaswamy et al., 1999; 10051603, Liu et al., 2005; 15988030, Karoui et al., 2004; 15026806, Gil et al., 2015; 25875300, Furnari et al., 1998; 9823298, Spinelli et al., 2015; 25527629, Mingo et al., 2018; 29706633, Wang et al., 2010; 20538496, Andr\u00e9s_Pons et al., 2007; 17942903, Butler et al., 2005; 15805158, Lee et al., 1999; 10555148, Georgescu et al., 1999; 10468583, Staal et al., 2002; 12085208, Nguyen et al., 2013; 24292679, Rahdar et al., 2009; 19114656, Das et al., 2003; 12808147, Wang et al., 2008; 18498243, Valiente et al., 2005; 15951562, Nguyen et al., 2015; 25263454, Shan et al., 2020; 32704382). In the Esophageal Adenocarcinoma dataset, PTEN mutations have been reported in 2.7% of tumors (cBio_Dulak et al., 2013; 23525077). PTEN loss has been reported in 14% of esophageal adenocarcinoma samples (Bettstetter et al., 2013; 23158210). Loss of PTEN has been observed primarily in advanced stage esophageal tumors, where it was associated with shorter disease_free and overall patient survival (Bettstetter et al., 2013; 23158210). In addition, absence of nuclear PTEN expression has been correlated with decreased survival in esophageal adenocarcinoma (Tachibana et al., 2002; 11932897). Another study reports that negative PTEN nuclear staining was associated with poor 10_year survival of patients with ESCC (Tachibana et al., 2002; 11932897). Activation of the PI3K_AKT_mTOR pathway, including through reduced expression of PTEN, is a common contributor to esophageal cancer, in both squamous cell and adenocarcinoma tumor types (Tachibana et al., 2002; 11932897, Sagatys et al., 2007; 17640711). PTEN loss or mutation leads to activation of the PI3K_AKT_mTOR pathway and may predict sensitivity to inhibitors of this pathway (Courtney et al., 2010; 20085938, Simpson and Parsons, 2001; 11237521, Patnaik et al., 2016; 27672108, Milella et al., 2017; 28220839). Clinical studies in gastric cancer have not observed an association between PTEN deficiency and response to the mTOR inhibitor everolimus (Voss et al., 2019; 30327302) or ipatasertib (Bang et al., 2019; 30592991). Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors (Mendes_Pereira et al., 2009; 20049735, Shen et al., 2013; 23881923, Chatterjee et al., 2013; 23565244, McCormick et al., 2016; 26905328, Forster et al., 2011; 21468130), and clinical benefit has been observed for patients with PTEN_altered breast cancer including triple negative breast cancer (Gruber et al., 2019; ASCO Abstract 3006, Eikesdal et al., 2021; 33242536), ovarian cancer (Dougherty et al., 2014; ASCO Abstract 5536), uterine leiomyosarcoma (Pan et al., 2021; 33970096), and endometrial cancer (Forster et al., 2011; 21468130) treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity (Sandhu et al., 2013; 23810788, Romero et al., 2020; 32988624, Piha_Paul et al., 2018; AACR Abstract A096). PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte_Duclos disease (LD), Bannayan_Riley_Ruvalcaba syndrome (BRRS), PTEN_related Proteus syndrome (PS), and Proteus_like syndrome (Blumenthal and Dennis, 2008; 18781191, Orloff and Eng, 2008; 18794875). The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients (Blumenthal and Dennis, 2008; 18781191, Zbuk and Eng, 2007; 17167516). The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder (Blumenthal and Dennis, 2008; 18781191). Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.", "Include": "true", "ClinicalTrialNote": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT05035745", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04551521", "Include": "true"}, {"nctId": "NCT03994796", "Include": "true"}, {"nctId": "NCT04991480", "Include": "true"}, {"nctId": "NCT05327010", "Include": "true"}, {"nctId": "NCT04317105", "Include": "true"}, {"nctId": "NCT02769962", "Include": "true"}, {"nctId": "NCT05142241", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "04", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "04"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2023). For patients with gastric cancer, increased TMB is reported to be associated with prolonged OS (Cai et al., 2020; 32141230, Zhao et al., 2021; 33510848, Wei et al., 2021; 33613701). One study observed that the OS and disease_free survival (DFS) benefits of postoperative chemotherapy were more pronounced in patients with TMB_low gastric cancer (stage Ib/II) compared to those with TMB_high; however, patients with stage III gastric cancer benefitted regardless of TMB level (Wang et al., 2021; 33687617). In esophageal cancer, patients with TMB_high who had not received radiotherapy had significantly reduced OS (p=0.038) compared to those with TMB_low (Yuan et al., 2019; 32165590). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P), anti_PD_L1/CTLA4 therapies (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61, Li et al., 2020; ASCO Abstract 6511, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). A Phase 2 multi_solid_tumor trial showed that bTMB \u226516 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD_1 inhibitor alone or in combination with a CTLA_4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non_small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single_agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb_16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511). In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB \u226528 Muts/Mb (approximate equivalency \u226514 Muts/Mb as measured by this assay) was associated with improved OS from a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Loree et al., 2021; ASCO GI Abstract 61, Chen et al., 2020; 32379280).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "KDM5A", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "KDM5A encodes a lysine_specific histone demethylase that potentiates the expression of genes involved in cellular proliferation, senescence, angiogenesis, and migration (Zeng et al., 2010; 19850045, Chicas et al., 2012; 22615382, Teng et al., 2013; 23722541, Li et al., 2014; 24716659, Lin et al., 2014; 25537453). KDM5A overexpression alters the transcriptional regulation of cell cycle genes, including CCND1, and a variety of cyclin_dependent kinase inhibitors (CDKIs), including CDKN1A, CDKN1B, and CDKN2A, and results in cell cycle progression (Zeng et al., 2010; 19850045, Teng et al., 2013; 23722541, Liang et al., 2013; 23922798, Jiping et al., 2013; 23794145, Vieira et al., 2014; 24200674, Li et al., 2014; 24716659). Additionally, elevated KDM5A expression and associated chromatin remodeling has been implicated in resistance to various tyrosine kinase inhibitors in vitro, including erlotinib and gefitinib (Sharma et al., 2010; 20371346, Dannenberg et al., 2010; 20371339, Hou et al., 2012; 22937203). KDM5A amplification has been reported with the highest incidence in TCGA datasets in ovarian serous cystadenocarcinoma (7.2%), testicular germ cell cancer (5.8%), pancreatic adenocarcinoma (4.3%), and lung squamous cell carcinoma (3.9%) (cBioPortal, Jan 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Elevated levels of KDM5A expression have also been reported in a range of solid tumor types (Hou et al., 2012; 22937203, Liang et al., 2013; 23922798, Teng et al., 2013; 23722541, Paolicchi et al., 2013; 23266085, Vieira et al., 2014; 24200674, Li et al., 2014; 24716659), and fusion of KDM5A to NUP98 has been documented in acute myeloid leukemia (van Zutven et al., 2006; 16419055, Wang et al., 2009; 19430464). KDM5A expression is significantly correlated with HIF_1alpha and VEGF expression, as well as tumor size, angiogenesis, and poor patient prognosis in lung cancer (Qi et al., 2014; 25162518). There are no targeted therapies available to directly address genomic alterations in KDM5A. However, multiple preclinical studies have identified potential targets in KDM5A amplified or activated cells that may respond to therapy. KDM5A_mediated chromatin remodeling induces CCND1 expression and represses CDKI expression (Zeng et al., 2010; 19850045, Teng et al., 2013; 23722541, Liang et al., 2013; 23922798, Jiping et al., 2013; 23794145, Vieira et al., 2014; 24200674); therefore, KDM5A activation or amplification may sensitize cells to CDK4/CDK6 inhibitors. Drug_resistant cell populations, characterized by elevated KDM5A expression, responded to histone deacetylase (HDAC) inhibition (Sharma et al., 2010; 20371346), suggesting that HDAC inhibitors may be a potential therapeutic option. KDM5A also induces expression of VEGF and promotes angiogenesis, oncogenic transformation, and tumorigenesis, which can be inhibited by KDM5A knockdown (Li et al., 2014; 24716659, Qi et al., 2014; 25162518), suggesting that tumors harboring KDM5A amplification may be sensitive to angiogenesis inhibitors, including kinase inhibitors that target the VEGF receptors, such as sunitinib, sorafenib, vandetanib, ponatinib, cabozantinib, regorafenib, pazopanib, and axitinib. However, these inhibitors have yet to be extensively tested in the context of KDM5A amplification or activation; therefore, it is not known if these therapeutic strategies are relevant.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI_H has been identified in 3.9% of gastric or esophageal adenocarcinomas (Huang et al., 2021; 3288412), 6.6% (5/76) of Barrett esophagus_associated adenocarcinomas (Farris et al., 2011; 21422910), 2.5% (2/79) gastroesophageal junction adenocarcinomas (Cancer Genome Atlas Research Network, 2017; 28052061), and 0_2.1% esophageal squamous cell carcinomas (Cancer Genome Atlas Research Network, 2017; 28052061, Huang et al., 2021; 32884129). In a small study of 27 patients with esophageal adenocarcinoma, no significant difference in disease free survival was observed between patients with MSS (9/27) or MSI_Low (18/27) tumors (HR = 0.61)(Evans et al., 2004; 15279904). In a study of 80 patients with primary Barrett esophagus\u2010associated adenocarcinoma, no association between MSI status and OS was observed (p= 0.19)(Kulke et al., 2001; 11301392). MSI_H tumors have been frequently associated with hypermethylation and loss of MLH1 expression in cancers of the upper gastrointestinal tract, including esophageal, gastroesophageal junction, and gastric adenocarcinomas (Fang et al., 2013; 23555086, Gu et al., 2009; 19621725, Sasaki et al., 2011; 22866067, Fleisher et al., 1999; 10070967, Vasavi et al., 2010; 21045259, Zhang et al., 2013; 24035280). On the basis of clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), retifanlimab, and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143, Berton et al., 2021; SITC Abstract 956), as well as PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (alone or in combination with tremelimumab) (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92, Pietrantonio et al., 2023; ASCO GI Abstract 358, Lee et al., 2023; ASCO GI abstract 401, Rubinstein et al., 2022; 36512912, Marie et al., 2021; 33811152). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "NFKBIA", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "NFKBIA encodes IkBa, an inhibitor of the NF_kappaB (NFkB)/REL complex. It has been reported to act as a tumor suppressor in Hodgkin\u2019s lymphoma (Weniger et al., 2016; 27221964, Liu et al., 2010; 20193848, Lake et al., 2009; 19507254, Osborne et al., 2005; 5858823, Cabannes et al., 1999; 10340377) and in glioblastoma (Bredel et al., 2011; 21175304, Zhao et al., 2014; 25215581, Patane et al., 2013; 24330732). NFKBIA has been reported to be amplified in cancer (Gao et al., 2013; 23550210) and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). In contrast, truncating mutations that result in loss of the majority of the IkBa protein are predicted to be inactivating. In the TCGA datasets, amplification of NFKBIA has been reported with the highest incidence in lung adenocarcinoma (11.7%)(Cancer Genome Atlas Research Network., 2014; 25079552), esophageal carcinoma (3.8%), prostate adenocarcinoma (3.4%)(cBio_Kumar et al., 2016; 26928463), lung squamous cell carcinoma (2.8%)(Cancer Genome Atlas Research Network., 2012; 22960745), and ovarian serous cystadenocarcinoma (2.6%) (cBioPortal, Jan 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Amplification or increased expression of NFKBIA in EGFR_mutant lung cancer has been reported to predict improved response to EGFR tyrosine kinase inhibitors (Bivona et al., 2011; 21430781)(Giannikopoulos et al., 2014; ASCO Abstract 8083). Certain NFKBIA polymorphisms, which may affect IkBa expression levels, have been studied as risk factors for some cancer types, although the data are mixed and conflicting (Zhao et al., 2014; 25215581, Geng et al., 2015; 26252270, Zhang et el., 2015; 26488500). There are no therapies that directly target NFKBIA amplification or expression.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "NOTCH3", "Include": "true", "Alterations": {"Alteration": {"Name": "rearrangement exon 6", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "13.05", "isEquivocal": "false", "name": "rearrangement exon 6"}}, "Interpretation": "NOTCH3 encodes a member of the NOTCH family of receptors, which are involved in cell fate determination and various developmental processes. Upon binding of membrane_bound ligands, NOTCH signaling involves cleavage of the NOTCH intracellular domain (NICD), which subsequently forms part of a transcription factor complex that regulates downstream target genes (Penton et al., 2012; 22306179, Kopan and Ilagan, 2009; 19379690). Although internal deletions that remove EGF repeats (7_10 and 21_22) have been shown in vitro to negatively affect ligand binding and reduce NOTCH3 transcriptional activity (Lin et al., 2010; 20068176), NOTCH1 and NOTCH2 rearrangements that eliminate the extracellular domain (ECD) have been observed in patients with breast cancer (Edwards and Howarth., 2012; 22424054, Robinson et al., 2011; 22101766) and T_cell acute lymphoblastic leukemia (T_ALL) (Haydu et al., 2012; 22510873), resulting in ligand_independent activation of NOTCH transcriptional activity and sensitivity to gamma_secretase inhibitors (Robinson et al., 2011; 22101766, Palomero et al., 2006; 16688224, Haydu et al., 2012; 22510873, Ashworth et al., 2010; 20852131, Sakamoto et al., 2005; 15561108). NOTCH3 intracellular domain (NICD) has also been shown to increase cell proliferation in vitro and tumorigenesis in vivo (De Salvo et al., 2014; 24797362), and a fusion of MIR143 to NOTCH3 NICD has been observed in benign glomus tumor, with a similar fusion involving NOTCH2 reported to upregulate NOTCH expression (Mosquera et al., 2013; 23999936). However, as it is unknown whether such alterations, as observed here, would lead to expression of NICD, the functional effect is unclear. NOTCH3 mutation has been observed in 0_2.3% of esophageal squamous cell carcinomas (cBio_Song et al., 2014; 24670651, cBio_Lin et al., 2014; 24686850). In the Broad Esophageal Adenocarcinoma dataset, NOTCH3 mutations have been reported in 1% of tumors (cBio_Dulak et al., 2013; 23525077). In other studies, NOTCH3 mutations were reported in 1/11 esophageal adenocarcinomas and 6_8% of esophageal squamous cell carcinomas (Agrawal et al., 2012; 22877736, Gao et al., 2014; 25151357). In a study of esophageal squamous cell carcinoma, increased NOTCH3 expression was identified as an adverse prognostic marker in multivariate analysis (HR=2.38, p=0.047) (Pramanik et al., 2019; DOI: 10.1093/annonc/mdz422.021). A study reported increased expression of NOTCH3, as well as NOTCH1, JAGGED1, and JAGGED2, in gastric cancer tissue compared to normal tissue, and an association of NOTCH3 overexpression with intestinal_type gastric cancer and with better patient prognosis (Kang et al., 2012; 22691042). However, a meta_analysis of 15 studies encompassing a total of 1547 gastric cancer cases reported significantly higher expression of NOTCH3 in diffuse type gastric cancer (Du et al., 2014; 25083094). A preclinical study also found that NOTCH3 expression increased in gastric cancer cell lines treated with 5_fluorouracil chemotherapy, suggesting that NOTCH3 may be a biomarker of drug resistance (Maeda et al., 2014; 24504010). Several approaches for inhibiting NOTCH3 signaling are being developed, including neutralizing NOTCH antibodies such as tarextumab (OMP_59R5) (Yen et al., 2015; 25934888), which targets NOTCH2 and NOTCH3, and pan_NOTCH inhibitors, such as gamma_secretase inhibitors (GSI) (Hu et al., 2014; 24743243, Konishi et al., 2007; 17804716, Xiao et al., 2011; 20838375). In a Phase 2 study, the GSI AL101 (BMS_906024) elicited PR in 15% (6/39) and SD in 54% (21/39) of patients with metastatic adenoid cystic carcinoma harboring NOTCH activating alterations (Ferrarotto et al., 2020; ESMO Abstract 919MO). Phase 2 studies have evaluated the efficacy of tarextumab in combination with chemotherapy in metastatic pancreatic cancer or extensive_stage small cell lung cancer, though NOTCH3 expression was not found to be a predictor of OS or PFS in either study (Hu et al., 2019; 31347292; O\u2019Reilly et al., 2015; Gastrointestinal Cancers Symposium Abstract 278, Daniel et al., 2017; ESMO Abstract 1530PD). As it is unclear if the rearrangement seen here results in expression of an oncogenic protein, it is not known whether these therapeutic approaches would be relevant.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "R273C", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "33.08", "isEquivocal": "false", "name": "R273C"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 is frequently mutated in cancers of the gastrointestinal tract, with alterations reported in 34\u201372% of esophageal, gastroesophageal junction, and gastric adenocarcinomas (Dulak et al., 2013; 23525077, Cancer Genome Atlas Research Network., 2014; 25079317, Sengpiel et al., 2009; 19160092, P\u00fchringer_Oppermann et al., 2006; 16538517). TP53 mutations have been observed in 61_93% of esophageal squamous cell carcinoma samples (cBio_Song et al., 2014; 24670651, cBio_Lin et al., 2014; 24686850, Sawada et al., 2016; 26873401). While some studies have reported no association between TP53 mutation status and prognosis in patients with esophageal carcinoma or gastroesophageal junction adenocarcinoma (Sengpiel et al., 2009; 19160092, P\u00fchringer_Oppermann et al., 2006; 16538517) others have associated TP53 mutation and elevated p53 expression with poor prognosis for patients with esophageal squamous cell carcinoma (Han et al., 2007; 17760650, Yamasaki et al., 2010; 19941080) or stomach cancer (Liu et al., 2012; 23285001, Wiksten et al., 2008; 18751407, Migliavacca et al., 2004; 15254976). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "Elevated Tumor Fraction", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Elevated Tumor Fraction"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction have high circulating_tumor DNA (ctDNA) content, and thus higher sensitivity for identifying genomic alterations. Such specimens are at a lower risk of false negative results. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "WT1", "Include": "true", "Alterations": {"Alteration": {"Name": "Q490_K491>H*", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "15.38", "isEquivocal": "false", "name": "Q490_K491>H*"}}, "Interpretation": "The WT1 gene encodes a zinc finger transcription factor, which has been described as both a tumor suppressor and oncogene in a variety of cancers, including Wilms tumor (nephroblastoma), a malignant tumor of the kidney found most commonly in children (Ruteshouser et al., 2008; 18311776). WT1 alterations that disrupt the N_terminal region (amino acids 74\u2013244, also 6\u2013180 in alternate transcripts) and/or zinc finger domain (amino acids 391\u2013506, also 323\u2013438 in alternate transcripts) are predicted to be inactivating (Maheswaran et al., 1998; 9553041, Yang et al., 2007; 17361230, Nachtigal et al., 1998; 9590178, Hossain et al., 2001; 11278460, Borel et al., 1996; 8810912). Missense mutations at codons 404, 462, and 464 (336, 394, and 396 in alternate transcripts) have been observed in patients with T_cell acute lymphoblastic leukemia (T_ALL)(Tosello et al., 2009; 19494353), acute myeloid leukemia (AML) post myelodysplastic syndrome (Mori et al., 1999; 10354161, King_Underwood et al., 1998; 9531607), Wilms tumor or the disorder Denys_Drash syndrome (Borel et al., 1996; 8810912, Chiang et al., 2008; 18197048, Royer_Pokora et al., 2004; 15150775, Tosello et al., 2009; 19494353, Santin et al., 2011; 21888862). Germline mutations in WT1 are associated with several rare genitourinary developmental and cancer syndromes, including Wilms tumor, WAGR syndrome, Denys_Drash syndrome, Frasier syndrome, nephrotic syndrome type 4, and Meacham syndrome (Rahman et al., 1996; 8696342, Breslow and Beckwith, 1982; 6278194, Drash et al., 1970; 4316066, Frasier et al., 1964; 14149008, Schumacher et al., 1998; 9607189, Meacham et al., 1991; 1844355). Wilms tumor, the most common of these, occurs in approximately 1:10,000 children and accounts for 7\u20138% of childhood cancers (Rahman et al., 1996; 8696342, Breslow and Beckwith, 1982; 6278194, Levitt, 2012; 21947271), and in the appropriate clinical context, germline testing of WT1 is recommended. WT1 alterations have been reported in Wilms tumors at frequencies ranging from 9% to 81%, with higher rates in bilateral Wilms tumors (Rakheja et al., 2014; 25190313, Scott et al., 2008; 18836444, Huff, 1998; 9781905, Haruta et al., 2012; 22409817, Kaneko et al., 2015; 25688735), and at lower frequencies (<8%) in various other solid tumors (COSMIC, Jan 2023)(Tate et al., 2019; 30371878). Reduced expression or aberrant methylation of WT1 has been reported in a variety of cancers including breast cancer, colorectal cancer, testicular germ cell tumors, and non_small cell lung carcinoma (NSCLC)(Loeb et al., 2001; 11221883, Lian et al., 2012; 22581028, Ayhan et al., 2012; 22825896, Xu et al., 2004; 15526363, Boublikova et al., 2016; 27085458), and low expression of WT1 in NSCLC was predictive of poor patient prognosis in one study (Hayashi et al., 2012; 22148937). However, the majority of solid tumors examined have been reported to overexpress WT1 (Ding et al., 2008; 18948947, Imielinski et al., 2012; 22980975, Ichinohasama et al., 2010; 20180815, Oji et al., 2002; 12115544, Wilsher and Cheerala, 2007; 17927581, Rosner et al., 2009; 19615003, Oji et al., 2003; 12901797, Bejrananda et al., 2011; 21896989). In several tumor types, overexpression of WT1 has been associated with poor prognosis (Sugiyama, 2010; 20395243, Bejrananda et al., 2011; 21896989, Garrido_Ruiz et al., 2010; 19638168). There are no approved therapies that target WT1 mutation. Preclinical studies in acute myeloid leukemia (AML) have shown that WT1 loss may disrupt interactions with the TET2 enzyme (Rampal et al., 2014; 25482556, Wang et al., 2015; 25601757, Sinha et al., 2015; 25398938) and, based on one clinical study, may confer sensitivity to the DNA methyltransferase (DNMT) inhibitor azacitidine in AML and myelodysplastic syndrome patients (Jo et al., 2013; ASH Abstract 1528). However, it is not known if this approach would be beneficial for solid tumors or in the context of WT1 mutation. WT1 peptide_based vaccines are being investigated in hematopoietic malignancies and solid cancers, although their relevance to WT1 mutation is unknown (Sugiyama, 2002; 12215010, Oka et al., 2003; 12894852, Oka et al., 2004; 15365188, Oka et al., 2006; 16918359, Keilholz et al., 2009; 19389880).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "CCND2", "Alteration": "amplification", "Title": "A Study of BPI_1178 in Patients With Advanced Solid Tumor and HR+/HER2_ Breast Cancer", "StudyPhase": "PHASE 1/2", "Target": "CDK6, CDK4, ER, Aromatase", "Locations": "Shanghai (China)", "NCTID": "NCT04282031", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "Genetic Testing in Guiding Treatment for Patients With Brain Metastases", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, CDK4, CDK6, PI3K, mTOR", "Locations": "Washington, Oregon, Idaho, Montana", "NCTID": "NCT03994796", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "(VELA) Study of BLU_222 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ER, CDK4, CDK6, CDK2", "Locations": "Illinois, Massachusetts, Arkansas, New York, Virginia, Texas, Florida", "NCTID": "NCT05252416", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "Palbociclib In Progressive Brain Metastases", "StudyPhase": "PHASE 2", "Target": "CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT02896335", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "The Finnish National Study to Facilitate Patient Access to Targeted Anti_cancer Drugs", "StudyPhase": "PHASE 2", "Target": "BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD_L1, MEK, CDK4, CDK6", "Locations": "Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)", "NCTID": "NCT05159245", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D_type Cyclins or Amplification of CDK4 or CDK6", "StudyPhase": "PHASE 2", "Target": "CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT03310879", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors", "StudyPhase": "PHASE 1", "Target": "CDK4, CDK6, ERK2, ERK1", "Locations": "North Carolina", "NCTID": "NCT03454035", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C218*", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)", "NCTID": "NCT02264678", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C218*", "Title": "Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)", "StudyPhase": "PHASE 1/2", "Target": "XPO1, PARP", "Locations": "Singapore (Singapore)", "NCTID": "NCT05035745", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C218*", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C218*", "Title": "CRAFT: The NCT_PMO_1602 Phase II Trial", "StudyPhase": "PHASE 2", "Target": "PD_L1, AKTs, MEK, BRAF, ALK, RET, ERBB2", "Locations": "L\u00fcbeck (Germany), W\u00fcrzburg (Germany), Mainz (Germany), Heidelberg (Germany), T\u00fcbingen (Germany)", "NCTID": "NCT04551521", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C218*", "Title": "Genetic Testing in Guiding Treatment for Patients With Brain Metastases", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, CDK4, CDK6, PI3K, mTOR", "Locations": "Washington, Oregon, Idaho, Montana", "NCTID": "NCT03994796", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C218*", "Title": "A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PARP, Pol theta", "Locations": "London (United Kingdom), Oklahoma, Connecticut, New York, Pennsylvania, Tennessee, Texas, Florida", "NCTID": "NCT04991480", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C218*", "Title": "Testing the Combination of the Anti_cancer Drugs ZEN003694 (ZEN_3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial", "StudyPhase": "PHASE 2", "Target": "PARP, BRD4, BRDT, BRD2, BRD3", "Locations": "Illinois, Texas, North Carolina, Georgia", "NCTID": "NCT05327010", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C218*", "Title": "Testing the Addition of an Anti_cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN", "StudyPhase": "PHASE 1/2", "Target": "PD_1, CTLA_4, PI3K", "Locations": "Toronto (Canada), Texas, Virginia", "NCTID": "NCT04317105", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C218*", "Title": "Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer", "StudyPhase": "PHASE 1/2", "Target": "PARP, TOP1", "Locations": "Maryland", "NCTID": "NCT02769962", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "C218*", "Title": "Testing the Combination of Anti_Cancer Drugs Talazoparib and Temozolomide in Patients >= 18 Years Old With Advanced Stage Rare Cancers, RARE 2 Study", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Maryland", "NCTID": "NCT05142241", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "11237521", "FullCitation": "Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521", "Include": "true"}, {"number": "1", "ReferenceId": "12857747", "FullCitation": "Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747", "Include": "true"}, {"number": "2", "ReferenceId": "21828076", "FullCitation": "Rodr\u00edguez_Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076", "Include": "true"}, {"number": "3", "ReferenceId": "23475934", "FullCitation": "He X, et al. Cancer Res. (2013) pmid: 23475934", "Include": "true"}, {"number": "4", "ReferenceId": "10866302", "FullCitation": "Han SY, et al. Cancer Res. (2000) pmid: 10866302", "Include": "true"}, {"number": "5", "ReferenceId": "9811831", "FullCitation": "Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831", "Include": "true"}, {"number": "6", "ReferenceId": "24498881", "FullCitation": "Pradella LM, et al. BMC Cancer (2014) pmid: 24498881", "Include": "true"}, {"number": "7", "ReferenceId": "21536651", "FullCitation": "Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651", "Include": "true"}, {"number": "8", "ReferenceId": "17213812", "FullCitation": "Denning G, et al. Oncogene (2007) pmid: 17213812", "Include": "true"}, {"number": "9", "ReferenceId": "16619501", "FullCitation": "Hlobilkova A, et al. Anticancer Res. () pmid: 16619501", "Include": "true"}, {"number": "10", "ReferenceId": "20718038", "FullCitation": "Redfern RE, et al. Protein Sci. (2010) pmid: 20718038", "Include": "true"}, {"number": "11", "ReferenceId": "22505997", "FullCitation": "Shenoy S, et al. PLoS ONE (2012) pmid: 22505997", "Include": "true"}, {"number": "12", "ReferenceId": "19329485", "FullCitation": "Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485", "Include": "true"}, {"number": "13", "ReferenceId": "16829519", "FullCitation": "Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519", "Include": "true"}, {"number": "14", "ReferenceId": "10555148", "FullCitation": "Lee JO, et al. Cell (1999) pmid: 10555148", "Include": "true"}, {"number": "15", "ReferenceId": "9635567", "FullCitation": "Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567", "Include": "true"}, {"number": "16", "ReferenceId": "9865913", "FullCitation": "Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913", "Include": "true"}, {"number": "17", "ReferenceId": "11051241", "FullCitation": "Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241", "Include": "true"}, {"number": "18", "ReferenceId": "22891331", "FullCitation": "Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331", "Include": "true"}, {"number": "19", "ReferenceId": "23066114", "FullCitation": "Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114", "Include": "true"}, {"number": "20", "ReferenceId": "19457929", "FullCitation": "Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929", "Include": "true"}, {"number": "21", "ReferenceId": "23995781", "FullCitation": "Liu J, et al. Oncogene (2014) pmid: 23995781", "Include": "true"}, {"number": "22", "ReferenceId": "11395408", "FullCitation": "Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408", "Include": "true"}, {"number": "23", "ReferenceId": "10807691", "FullCitation": "De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691", "Include": "true"}, {"number": "24", "ReferenceId": "10051603", "FullCitation": "Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603", "Include": "true"}, {"number": "25", "ReferenceId": "15988030", "FullCitation": "Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030", "Include": "true"}, {"number": "26", "ReferenceId": "15026806", "FullCitation": "Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806", "Include": "true"}, {"number": "27", "ReferenceId": "25875300", "FullCitation": "Gil A, et al. PLoS ONE (2015) pmid: 25875300", "Include": "true"}, {"number": "28", "ReferenceId": "9823298", "FullCitation": "Furnari FB, et al. Cancer Res. (1998) pmid: 9823298", "Include": "true"}, {"number": "29", "ReferenceId": "25527629", "FullCitation": "Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629", "Include": "true"}, {"number": "30", "ReferenceId": "29706633", "FullCitation": "Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633", "Include": "true"}, {"number": "31", "ReferenceId": "20538496", "FullCitation": "Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496", "Include": "true"}, {"number": "32", "ReferenceId": "17942903", "FullCitation": "Andr\u00e9s_Pons A, et al. Cancer Res. (2007) pmid: 17942903", "Include": "true"}, {"number": "33", "ReferenceId": "15805158", "FullCitation": "Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158", "Include": "true"}, {"number": "34", "ReferenceId": "10468583", "FullCitation": "Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583", "Include": "true"}, {"number": "35", "ReferenceId": "12085208", "FullCitation": "Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208", "Include": "true"}, {"number": "36", "ReferenceId": "24292679", "FullCitation": "Nguyen HN, et al. Oncogene (2014) pmid: 24292679", "Include": "true"}, {"number": "37", "ReferenceId": "19114656", "FullCitation": "Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656", "Include": "true"}, {"number": "38", "ReferenceId": "12808147", "FullCitation": "Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147", "Include": "true"}, {"number": "39", "ReferenceId": "18498243", "FullCitation": "Wang X, et al. Biochem. J. (2008) pmid: 18498243", "Include": "true"}, {"number": "40", "ReferenceId": "15951562", "FullCitation": "Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562", "Include": "true"}, {"number": "41", "ReferenceId": "25263454", "FullCitation": "Nguyen HN, et al. Oncogene (2015) pmid: 25263454", "Include": "true"}, {"number": "42", "ReferenceId": "32704382", "FullCitation": "Shan L, et al. Cell Discov (2020) pmid: 32704382", "Include": "true"}, {"number": "43", "ReferenceId": "23525077", "FullCitation": "Dulak AM, et al. Nat. Genet. (2013) pmid: 23525077", "Include": "true"}, {"number": "44", "ReferenceId": "23158210", "FullCitation": "Bettstetter M, et al. Hum. Pathol. (2013) pmid: 23158210", "Include": "true"}, {"number": "45", "ReferenceId": "11932897", "FullCitation": "Tachibana M, et al. Cancer (2002) pmid: 11932897", "Include": "true"}, {"number": "46", "ReferenceId": "17640711", "FullCitation": "Sagatys E, et al. Hum. Pathol. (2007) pmid: 17640711", "Include": "true"}, {"number": "47", "ReferenceId": "20085938", "FullCitation": "Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938", "Include": "true"}, {"number": "48", "ReferenceId": "27672108", "FullCitation": "Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108", "Include": "true"}, {"number": "49", "ReferenceId": "28220839", "FullCitation": "Milella M, et al. Sci Rep (2017) pmid: 28220839", "Include": "true"}, {"number": "50", "ReferenceId": "30327302", "FullCitation": "Voss MH, et al. Clin. Cancer Res. (2018) pmid: 30327302", "Include": "true"}, {"number": "51", "ReferenceId": "30592991", "FullCitation": "Bang YJ, et al. Eur J Cancer (2019) pmid: 30592991", "Include": "true"}, {"number": "52", "ReferenceId": "20049735", "FullCitation": "Mendes_Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735", "Include": "true"}, {"number": "53", "ReferenceId": "23881923", "FullCitation": "Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923", "Include": "true"}, {"number": "54", "ReferenceId": "23565244", "FullCitation": "Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244", "Include": "true"}, {"number": "55", "ReferenceId": "26905328", "FullCitation": "McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328", "Include": "true"}, {"number": "56", "ReferenceId": "21468130", "FullCitation": "Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130", "Include": "true"}, {"number": "57", "ReferenceId": "33242536", "FullCitation": "Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536", "Include": "true"}, {"number": "58", "ReferenceId": "33970096", "FullCitation": "Pan M, et al. Perm J (2021) pmid: 33970096", "Include": "true"}, {"number": "59", "ReferenceId": "23810788", "FullCitation": "Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788", "Include": "true"}, {"number": "60", "ReferenceId": "32988624", "FullCitation": "Romero I, et al. Gynecol Oncol (2020) pmid: 32988624", "Include": "true"}, {"number": "61", "ReferenceId": "18781191", "FullCitation": "Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191", "Include": "true"}, {"number": "62", "ReferenceId": "18794875", "FullCitation": "Orloff MS, et al. Oncogene (2008) pmid: 18794875", "Include": "true"}, {"number": "63", "ReferenceId": "17167516", "FullCitation": "Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516", "Include": "true"}, {"number": "64", "ReferenceId": "19860666", "FullCitation": "Katoh Y, et al. Curr. Mol. Med. (2009) pmid: 19860666", "Include": "true"}, {"number": "65", "ReferenceId": "16301994", "FullCitation": "White PC, et al. Oncogene (2006) pmid: 16301994", "Include": "true"}, {"number": "66", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "67", "ReferenceId": "24071852", "FullCitation": "Zack TI, et al. Nat. Genet. (2013) pmid: 24071852", "Include": "true"}, {"number": "68", "ReferenceId": "20164920", "FullCitation": "Beroukhim R, et al. Nature (2010) pmid: 20164920", "Include": "true"}, {"number": "69", "ReferenceId": "28052061", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2017) pmid: 28052061", "Include": "true"}, {"number": "70", "ReferenceId": "15707582", "FullCitation": "Busk PK, et al. Exp. Cell Res. (2005) pmid: 15707582", "Include": "true"}, {"number": "71", "ReferenceId": "12695654", "FullCitation": "Busk PK, et al. Cell Cycle () pmid: 12695654", "Include": "true"}, {"number": "72", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "73", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "74", "ReferenceId": "22306179", "FullCitation": "Penton AL, et al. Semin. Cell Dev. Biol. (2012) pmid: 22306179", "Include": "true"}, {"number": "75", "ReferenceId": "19379690", "FullCitation": "Kopan R, et al. Cell (2009) pmid: 19379690", "Include": "true"}, {"number": "76", "ReferenceId": "20068176", "FullCitation": "Lin L, et al. Cancer Res. (2010) pmid: 20068176", "Include": "true"}, {"number": "77", "ReferenceId": "22424054", "FullCitation": "Edwards PA, et al. Breast Cancer Res. (2012) pmid: 22424054", "Include": "true"}, {"number": "78", "ReferenceId": "22101766", "FullCitation": "Robinson DR, et al. Nat. Med. (2011) pmid: 22101766", "Include": "true"}, {"number": "79", "ReferenceId": "22510873", "FullCitation": "Haydu JE, et al. Blood (2012) pmid: 22510873", "Include": "true"}, {"number": "80", "ReferenceId": "16688224", "FullCitation": "Palomero T, et al. Leukemia (2006) pmid: 16688224", "Include": "true"}, {"number": "81", "ReferenceId": "20852131", "FullCitation": "Ashworth TD, et al. Blood (2010) pmid: 20852131", "Include": "true"}, {"number": "82", "ReferenceId": "15561108", "FullCitation": "Sakamoto K, et al. Exp. Cell Res. (2005) pmid: 15561108", "Include": "true"}, {"number": "83", "ReferenceId": "24797362", "FullCitation": "De Salvo M, et al. PLoS ONE (2014) pmid: 24797362", "Include": "true"}, {"number": "84", "ReferenceId": "23999936", "FullCitation": "Mosquera JM, et al. Genes Chromosomes Cancer (2013) pmid: 23999936", "Include": "true"}, {"number": "85", "ReferenceId": "24670651", "FullCitation": "Song Y, et al. Nature (2014) pmid: 24670651", "Include": "true"}, {"number": "86", "ReferenceId": "24686850", "FullCitation": "Lin DC, et al. Nat. Genet. (2014) pmid: 24686850", "Include": "true"}, {"number": "87", "ReferenceId": "22877736", "FullCitation": "Agrawal N, et al. Cancer Discov (2012) pmid: 22877736", "Include": "true"}, {"number": "88", "ReferenceId": "25151357", "FullCitation": "Gao YB, et al. Nat. Genet. (2014) pmid: 25151357", "Include": "true"}, {"number": "89", "ReferenceId": "22691042", "FullCitation": "Kang H, et al. Histopathology (2012) pmid: 22691042", "Include": "true"}, {"number": "90", "ReferenceId": "25083094", "FullCitation": "Du X, et al. World J. Gastroenterol. (2014) pmid: 25083094", "Include": "true"}, {"number": "91", "ReferenceId": "24504010", "FullCitation": "Maeda O, et al. Oncol. Rep. (2014) pmid: 24504010", "Include": "true"}, {"number": "92", "ReferenceId": "25934888", "FullCitation": "Yen WC, et al. Clin. Cancer Res. (2015) pmid: 25934888", "Include": "true"}, {"number": "93", "ReferenceId": "24743243", "FullCitation": "Hu W, et al. Cancer Res. (2014) pmid: 24743243", "Include": "true"}, {"number": "94", "ReferenceId": "17804716", "FullCitation": "Konishi J, et al. Cancer Res. (2007) pmid: 17804716", "Include": "true"}, {"number": "95", "ReferenceId": "20838375", "FullCitation": "Xiao Y, et al. Oncogene (2011) pmid: 20838375", "Include": "true"}, {"number": "96", "ReferenceId": "31347292", "FullCitation": "Hu ZI, et al. Cancer Med (2019) pmid: 31347292", "Include": "true"}, {"number": "97", "ReferenceId": "19850045", "FullCitation": "Zeng J, et al. Gastroenterology (2010) pmid: 19850045", "Include": "true"}, {"number": "98", "ReferenceId": "22615382", "FullCitation": "Chicas A, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22615382", "Include": "true"}, {"number": "99", "ReferenceId": "23722541", "FullCitation": "Teng YC, et al. Cancer Res. (2013) pmid: 23722541", "Include": "true"}, {"number": "100", "ReferenceId": "24716659", "FullCitation": "Li L, et al. Mol. Cancer (2014) pmid: 24716659", "Include": "true"}, {"number": "101", "ReferenceId": "25537453", "FullCitation": "Lin W, et al. Mol. Cancer Res. (2015) pmid: 25537453", "Include": "true"}, {"number": "102", "ReferenceId": "23922798", "FullCitation": "Liang X, et al. PLoS ONE (2013) pmid: 23922798", "Include": "true"}, {"number": "103", "ReferenceId": "23794145", "FullCitation": "Jiping Z, et al. J. Cell. Biochem. (2013) pmid: 23794145", "Include": "true"}, {"number": "104", "ReferenceId": "24200674", "FullCitation": "Vieira FQ, et al. Endocr. Relat. Cancer (2014) pmid: 24200674", "Include": "true"}, {"number": "105", "ReferenceId": "20371346", "FullCitation": "Sharma SV, et al. Cell (2010) pmid: 20371346", "Include": "true"}, {"number": "106", "ReferenceId": "20371339", "FullCitation": "Dannenberg JH, et al. Cell (2010) pmid: 20371339", "Include": "true"}, {"number": "107", "ReferenceId": "22937203", "FullCitation": "Hou J, et al. Am J Transl Res (2012) pmid: 22937203", "Include": "true"}, {"number": "108", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "109", "ReferenceId": "23266085", "FullCitation": "Paolicchi E, et al. Crit. Rev. Oncol. Hematol. (2013) pmid: 23266085", "Include": "true"}, {"number": "110", "ReferenceId": "16419055", "FullCitation": "van Zutven LJ, et al. Genes Chromosomes Cancer (2006) pmid: 16419055", "Include": "true"}, {"number": "111", "ReferenceId": "19430464", "FullCitation": "Wang GG, et al. Nature (2009) pmid: 19430464", "Include": "true"}, {"number": "112", "ReferenceId": "25162518", "FullCitation": "Qi L, et al. PLoS ONE (2014) pmid: 25162518", "Include": "true"}, {"number": "113", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "114", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "115", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "116", "ReferenceId": "3288412", "FullCitation": "Clin Neurosurg (1988) pmid: 3288412", "Include": "true"}, {"number": "117", "ReferenceId": "21422910", "FullCitation": "Farris AB, et al. Am. J. Surg. Pathol. (2011) pmid: 21422910", "Include": "true"}, {"number": "118", "ReferenceId": "32884129", "FullCitation": "Huang RSP, et al. Mod Pathol (2021) pmid: 32884129", "Include": "true"}, {"number": "119", "ReferenceId": "15279904", "FullCitation": "Evans SC, et al. Cancer Lett (2004) pmid: 15279904", "Include": "true"}, {"number": "120", "ReferenceId": "11301392", "FullCitation": "Kulke MH, et al. Cancer (2001) pmid: 11301392", "Include": "true"}, {"number": "121", "ReferenceId": "23555086", "FullCitation": "Fang WL, et al. Biomed Res Int (2013) pmid: 23555086", "Include": "true"}, {"number": "122", "ReferenceId": "19621725", "FullCitation": "Gu M, et al. Hepatogastroenterology () pmid: 19621725", "Include": "true"}, {"number": "123", "ReferenceId": "22866067", "FullCitation": "Sasaki S, et al. Oncol Lett (2011) pmid: 22866067", "Include": "true"}, {"number": "124", "ReferenceId": "10070967", "FullCitation": "Fleisher AS, et al. Cancer Res. (1999) pmid: 10070967", "Include": "true"}, {"number": "125", "ReferenceId": "21045259", "FullCitation": "Vasavi M, et al. Cancer Biomark (2010) pmid: 21045259", "Include": "true"}, {"number": "126", "ReferenceId": "24035280", "FullCitation": "Zhang LH, et al. Pathol. Res. Pract. (2013) pmid: 24035280", "Include": "true"}, {"number": "127", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "128", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "129", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "130", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "131", "ReferenceId": "35322232", "FullCitation": "Shitara K, et al. Nature (2022) pmid: 35322232", "Include": "true"}, {"number": "132", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "133", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "134", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "135", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "136", "ReferenceId": "36512912", "FullCitation": "Rubinstein MM, et al. Gynecol Oncol (2022) pmid: 36512912", "Include": "true"}, {"number": "137", "ReferenceId": "33811152", "FullCitation": "Kanikarla Marie P, et al. Clin Cancer Res (2021) pmid: 33811152", "Include": "true"}, {"number": "138", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "139", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "140", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "141", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "142", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "143", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "144", "ReferenceId": "25079317", "FullCitation": "Nature (2014) pmid: 25079317", "Include": "true"}, {"number": "145", "ReferenceId": "19160092", "FullCitation": "Sengpiel C, et al. Cancer Invest. (2009) pmid: 19160092", "Include": "true"}, {"number": "146", "ReferenceId": "16538517", "FullCitation": "P\u00fchringer_Oppermann F, et al. J. Cancer Res. Clin. Oncol. (2006) pmid: 16538517", "Include": "true"}, {"number": "147", "ReferenceId": "26873401", "FullCitation": "Sawada G, et al. Gastroenterology (2016) pmid: 26873401", "Include": "true"}, {"number": "148", "ReferenceId": "17760650", "FullCitation": "Han U, et al. Dis. Esophagus (2007) pmid: 17760650", "Include": "true"}, {"number": "149", "ReferenceId": "19941080", "FullCitation": "Yamasaki M, et al. Ann. Surg. Oncol. (2010) pmid: 19941080", "Include": "true"}, {"number": "150", "ReferenceId": "23285001", "FullCitation": "Liu X, et al. PLoS ONE (2012) pmid: 23285001", "Include": "true"}, {"number": "151", "ReferenceId": "18751407", "FullCitation": "Wiksten JP, et al. Anticancer Res. () pmid: 18751407", "Include": "true"}, {"number": "152", "ReferenceId": "15254976", "FullCitation": "Migliavacca M, et al. J. Cell. Physiol. (2004) pmid: 15254976", "Include": "true"}, {"number": "153", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "154", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "155", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "156", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "157", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "158", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "159", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "160", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "161", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "162", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "163", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "164", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "165", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "166", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "167", "ReferenceId": "36084396", "FullCitation": "Park H, et al. ESMO Open (2022) pmid: 36084396", "Include": "true"}, {"number": "168", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "169", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "170", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "171", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "172", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "173", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "174", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "175", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "176", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "177", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "178", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "179", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "180", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "181", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "182", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "183", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "184", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "185", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "186", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "187", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "188", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "189", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "190", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "191", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "192", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "193", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "194", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "195", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "196", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "197", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "198", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "199", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "200", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}, {"number": "201", "ReferenceId": "27221964", "FullCitation": "Weniger MA, et al. Semin. Cancer Biol. (2016) pmid: 27221964", "Include": "true"}, {"number": "202", "ReferenceId": "20193848", "FullCitation": "Liu X, et al. Cancer Genet. Cytogenet. (2010) pmid: 20193848", "Include": "true"}, {"number": "203", "ReferenceId": "19507254", "FullCitation": "Lake A, et al. Int. J. Cancer (2009) pmid: 19507254", "Include": "true"}, {"number": "204", "ReferenceId": "5858823", "FullCitation": "Birnstiel ML, et al. Arch Biol (Liege) (1965) pmid: 5858823", "Include": "true"}, {"number": "205", "ReferenceId": "10340377", "FullCitation": "Cabannes E, et al. Oncogene (1999) pmid: 10340377", "Include": "true"}, {"number": "206", "ReferenceId": "21175304", "FullCitation": "Bredel M, et al. N. Engl. J. Med. (2011) pmid: 21175304", "Include": "true"}, {"number": "207", "ReferenceId": "25215581", "FullCitation": "Zhao Z, et al. Int. J. Mol. Med. (2014) pmid: 25215581", "Include": "true"}, {"number": "208", "ReferenceId": "24330732", "FullCitation": "Patan\u00e8 M, et al. Mol. Cancer (2013) pmid: 24330732", "Include": "true"}, {"number": "209", "ReferenceId": "25079552", "FullCitation": "Nature (2014) pmid: 25079552", "Include": "true"}, {"number": "210", "ReferenceId": "26928463", "FullCitation": "Kumar A, et al. Nat. Med. (2016) pmid: 26928463", "Include": "true"}, {"number": "211", "ReferenceId": "22960745", "FullCitation": "Nature (2012) pmid: 22960745", "Include": "true"}, {"number": "212", "ReferenceId": "21430781", "FullCitation": "Bivona TG, et al. Nature (2011) pmid: 21430781", "Include": "true"}, {"number": "213", "ReferenceId": "26252270", "FullCitation": "Geng P, et al. Medicine (Baltimore) (2015) pmid: 26252270", "Include": "true"}, {"number": "214", "ReferenceId": "26488500", "FullCitation": "Zhang M, et al. Med. Sci. Monit. (2015) pmid: 26488500", "Include": "true"}, {"number": "215", "ReferenceId": "18311776", "FullCitation": "Ruteshouser EC, et al. Genes Chromosomes Cancer (2008) pmid: 18311776", "Include": "true"}, {"number": "216", "ReferenceId": "9553041", "FullCitation": "Maheswaran S, et al. Genes Dev. (1998) pmid: 9553041", "Include": "true"}, {"number": "217", "ReferenceId": "17361230", "FullCitation": "Yang L, et al. Leukemia (2007) pmid: 17361230", "Include": "true"}, {"number": "218", "ReferenceId": "9590178", "FullCitation": "Nachtigal MW, et al. Cell (1998) pmid: 9590178", "Include": "true"}, {"number": "219", "ReferenceId": "11278460", "FullCitation": "Hossain A, et al. J. Biol. Chem. (2001) pmid: 11278460", "Include": "true"}, {"number": "220", "ReferenceId": "8810912", "FullCitation": "Borel F, et al. Biochemistry (1996) pmid: 8810912", "Include": "true"}, {"number": "221", "ReferenceId": "19494353", "FullCitation": "Tosello V, et al. Blood (2009) pmid: 19494353", "Include": "true"}, {"number": "222", "ReferenceId": "10354161", "FullCitation": "Mori N, et al. Br. J. Haematol. (1999) pmid: 10354161", "Include": "true"}, {"number": "223", "ReferenceId": "9531607", "FullCitation": "King_Underwood L, et al. Blood (1998) pmid: 9531607", "Include": "true"}, {"number": "224", "ReferenceId": "18197048", "FullCitation": "Chiang PW, et al. Curr. Opin. Pediatr. (2008) pmid: 18197048", "Include": "true"}, {"number": "225", "ReferenceId": "15150775", "FullCitation": "Royer_Pokora B, et al. Am. J. Med. Genet. A (2004) pmid: 15150775", "Include": "true"}, {"number": "226", "ReferenceId": "21888862", "FullCitation": "Sant\u00edn S, et al. Clin. Nephrol. (2011) pmid: 21888862", "Include": "true"}, {"number": "227", "ReferenceId": "8696342", "FullCitation": "Rahman N, et al. Nat. Genet. (1996) pmid: 8696342", "Include": "true"}, {"number": "228", "ReferenceId": "6278194", "FullCitation": "Breslow NE, et al. J. Natl. Cancer Inst. (1982) pmid: 6278194", "Include": "true"}, {"number": "229", "ReferenceId": "4316066", "FullCitation": "Drash A, et al. J. Pediatr. (1970) pmid: 4316066", "Include": "true"}, {"number": "230", "ReferenceId": "14149008", "FullCitation": "FRASIER SD, et al. J. Pediatr. (1964) pmid: 14149008", "Include": "true"}, {"number": "231", "ReferenceId": "9607189", "FullCitation": "Schumacher V, et al. Kidney Int. (1998) pmid: 9607189", "Include": "true"}, {"number": "232", "ReferenceId": "1844355", "FullCitation": "Meacham LR, et al. Am. J. Med. Genet. (1991) pmid: 1844355", "Include": "true"}, {"number": "233", "ReferenceId": "21947271", "FullCitation": "Pediatr. Nephrol. (2012) pmid: 21947271", "Include": "true"}, {"number": "234", "ReferenceId": "25190313", "FullCitation": "Rakheja D, et al. Nat Commun (2014) pmid: 25190313", "Include": "true"}, {"number": "235", "ReferenceId": "18836444", "FullCitation": "Scott RH, et al. Nat. Genet. (2008) pmid: 18836444", "Include": "true"}, {"number": "236", "ReferenceId": "9781905", "FullCitation": "Am. J. Med. Genet. (1998) pmid: 9781905", "Include": "true"}, {"number": "237", "ReferenceId": "22409817", "FullCitation": "Haruta M, et al. Cancer Sci. (2012) pmid: 22409817", "Include": "true"}, {"number": "238", "ReferenceId": "25688735", "FullCitation": "Kaneko Y, et al. Br. J. Cancer (2015) pmid: 25688735", "Include": "true"}, {"number": "239", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "240", "ReferenceId": "11221883", "FullCitation": "Loeb DM, et al. Cancer Res. (2001) pmid: 11221883", "Include": "true"}, {"number": "241", "ReferenceId": "22581028", "FullCitation": "Lian ZQ, et al. Int. J. Oncol. (2012) pmid: 22581028", "Include": "true"}, {"number": "242", "ReferenceId": "22825896", "FullCitation": "Ayhan SS, et al. Cardiol J (2012) pmid: 22825896", "Include": "true"}, {"number": "243", "ReferenceId": "15526363", "FullCitation": "Xu XL, et al. World J. Gastroenterol. (2004) pmid: 15526363", "Include": "true"}, {"number": "244", "ReferenceId": "27085458", "FullCitation": "Boublikova L, et al. Cancer Lett. (2016) pmid: 27085458", "Include": "true"}, {"number": "245", "ReferenceId": "22148937", "FullCitation": "Hayashi S, et al. Cancer Invest. (2012) pmid: 22148937", "Include": "true"}, {"number": "246", "ReferenceId": "18948947", "FullCitation": "Ding L, et al. Nature (2008) pmid: 18948947", "Include": "true"}, {"number": "247", "ReferenceId": "22980975", "FullCitation": "Imielinski M, et al. Cell (2012) pmid: 22980975", "Include": "true"}, {"number": "248", "ReferenceId": "20180815", "FullCitation": "Ichinohasama R, et al. Cancer Sci. (2010) pmid: 20180815", "Include": "true"}, {"number": "249", "ReferenceId": "12115544", "FullCitation": "Oji Y, et al. Int. J. Cancer (2002) pmid: 12115544", "Include": "true"}, {"number": "250", "ReferenceId": "17927581", "FullCitation": "Wilsher M, et al. Histopathology (2007) pmid: 17927581", "Include": "true"}, {"number": "251", "ReferenceId": "19615003", "FullCitation": "Rosner K, et al. J. Cutan. Pathol. (2009) pmid: 19615003", "Include": "true"}, {"number": "252", "ReferenceId": "12901797", "FullCitation": "Oji Y, et al. Cancer Sci. (2003) pmid: 12901797", "Include": "true"}, {"number": "253", "ReferenceId": "21896989", "FullCitation": "Bejrananda T, et al. Cancer Biomark () pmid: 21896989", "Include": "true"}, {"number": "254", "ReferenceId": "20395243", "FullCitation": "Jpn. J. Clin. Oncol. (2010) pmid: 20395243", "Include": "true"}, {"number": "255", "ReferenceId": "19638168", "FullCitation": "Garrido_Ruiz MC, et al. J. Cutan. Pathol. (2010) pmid: 19638168", "Include": "true"}, {"number": "256", "ReferenceId": "25482556", "FullCitation": "Rampal R, et al. Cell Rep (2014) pmid: 25482556", "Include": "true"}, {"number": "257", "ReferenceId": "25601757", "FullCitation": "Wang Y, et al. Mol. Cell (2015) pmid: 25601757", "Include": "true"}, {"number": "258", "ReferenceId": "25398938", "FullCitation": "Sinha S, et al. Blood (2015) pmid: 25398938", "Include": "true"}, {"number": "259", "ReferenceId": "12215010", "FullCitation": "Int. J. Hematol. (2002) pmid: 12215010", "Include": "true"}, {"number": "260", "ReferenceId": "12894852", "FullCitation": "Oka Y, et al. Int. J. Hematol. (2003) pmid: 12894852", "Include": "true"}, {"number": "261", "ReferenceId": "15365188", "FullCitation": "Oka Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2004) pmid: 15365188", "Include": "true"}, {"number": "262", "ReferenceId": "16918359", "FullCitation": "Oka Y, et al. Curr. Med. Chem. (2006) pmid: 16918359", "Include": "true"}, {"number": "263", "ReferenceId": "19389880", "FullCitation": "Keilholz U, et al. Blood (2009) pmid: 19389880", "Include": "true"}, {"number": "264", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "265", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "266", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "267", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "268", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "269", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "270", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "271", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "272", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "273", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "274", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "275", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "276", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "277", "ReferenceId": "32141230", "FullCitation": "Cai L, et al. Cancer Commun (Lond) (2020) pmid: 32141230", "Include": "true"}, {"number": "278", "ReferenceId": "33510848", "FullCitation": "Zhao DY, et al. World J Gastrointest Oncol (2021) pmid: 33510848", "Include": "true"}, {"number": "279", "ReferenceId": "33613701", "FullCitation": "Wei XL, et al. Ther Adv Med Oncol (2021) pmid: 33613701", "Include": "true"}, {"number": "280", "ReferenceId": "33687617", "FullCitation": "Wang D, et al. Gastric Cancer (2021) pmid: 33687617", "Include": "true"}, {"number": "281", "ReferenceId": "32165590", "FullCitation": "Yuan C, et al. Aging (Albany NY) (2020) pmid: 32165590", "Include": "true"}, {"number": "282", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "283", "ReferenceId": "32379280", "FullCitation": "Chen EX, et al. JAMA Oncol (2020) pmid: 32379280", "Include": "true"}, {"number": "284", "ReferenceId": "32271377", "FullCitation": "Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377", "Include": "true"}, {"number": "285", "ReferenceId": "33355200", "FullCitation": "Si H, et al. Clin Cancer Res (2021) pmid: 33355200", "Include": "true"}, {"number": "286", "ReferenceId": "34800700", "FullCitation": "Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_05_11 20:47:21", "OpName": "Melissa Krystel_Whittemore, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Melissa Krystel_Whittemore, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "4 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "38%"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "ESOPHAGUS", "disease_ontology": "Esophagus cancer (NOS)", "flowcell_analysis": "2000029002", "gender": "male", "pathology_diagnosis": "Esophageal Cancer", "pipeline_version": "v3.22.0", "purity_assessment": "34.1", "specimen": "ORD_1623178_01*US1548766.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1623178_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1548766.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.0017", "cds_effect": "1024G>A", "depth": "2897", "equivocal": "false", "functional_effect": "missense", "gene": "FOXL2", "percent_reads": "0.17", "position": "chr3:138664541", "protein_effect": "G342S", "status": "unknown", "strand": "_", "transcript": "NM_023067", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.0034", "cds_effect": "383_384AG>GT", "depth": "7158", "equivocal": "false", "functional_effect": "missense", "gene": "PTEN", "percent_reads": "0.34", "position": "chr10:89692899", "protein_effect": "K128S", "status": "unknown", "strand": "+", "transcript": "NM_000314", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.4115", "cds_effect": "364G>T", "depth": "469", "equivocal": "false", "functional_effect": "missense", "gene": "MAP3K1", "percent_reads": "41.15", "position": "chr5:56111764", "protein_effect": "A122S", "status": "unknown", "strand": "+", "transcript": "NM_005921", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.178", "cds_effect": "1355A>G", "depth": "500", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3R1", "percent_reads": "17.8", "position": "chr5:67589592", "protein_effect": "Y452C", "status": "unknown", "strand": "+", "transcript": "NM_181523", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.0067", "cds_effect": "1664_1665TG>GT", "depth": "1048", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3CB", "percent_reads": "0.67", "position": "chr3:138417854", "protein_effect": "M555S", "status": "unknown", "strand": "_", "transcript": "NM_006219", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.0082", "cds_effect": "654C>A", "depth": "6691", "equivocal": "false", "functional_effect": "nonsense", "gene": "PTEN", "percent_reads": "0.82", "position": "chr10:89717629", "protein_effect": "C218*", "status": "known", "strand": "+", "transcript": "NM_000314", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.005", "cds_effect": "1235G>A", "depth": "2020", "equivocal": "false", "functional_effect": "nonsense", "gene": "KLHL6", "percent_reads": "0.5", "position": "chr3:183211982", "protein_effect": "W412*", "status": "unknown", "strand": "_", "transcript": "NM_130446", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.001", "cds_effect": "4951T>G", "depth": "8634", "equivocal": "false", "functional_effect": "missense", "gene": "ATR", "percent_reads": "0.1", "position": "chr3:142226853", "protein_effect": "Y1651D", "status": "unknown", "strand": "_", "transcript": "NM_001184", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.0014", "cds_effect": "1066G>A", "depth": "6539", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "0.14", "position": "chr17:7573961", "protein_effect": "G356R", "status": "unknown", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.3835", "cds_effect": "1388T>A", "depth": "5559", "equivocal": "false", "functional_effect": "missense", "gene": "FGFR2", "percent_reads": "38.35", "position": "chr10:123263355", "protein_effect": "V463D", "status": "unknown", "strand": "_", "transcript": "NM_000141", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.5049", "cds_effect": "2638C>A", "depth": "612", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3C2G", "percent_reads": "50.49", "position": "chr12:18644460", "protein_effect": "P880T", "status": "unknown", "strand": "+", "transcript": "NM_004570", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.3722", "cds_effect": "482C>G", "depth": "403", "equivocal": "false", "functional_effect": "missense", "gene": "GATA4", "percent_reads": "37.22", "position": "chr8:11566303", "protein_effect": "P161R", "status": "unknown", "strand": "+", "transcript": "NM_002052", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.0028", "cds_effect": "1164G>T", "depth": "1786", "equivocal": "false", "functional_effect": "missense", "gene": "TYRO3", "percent_reads": "0.28", "position": "chr15:41861132", "protein_effect": "K388N", "status": "unknown", "strand": "+", "transcript": "NM_006293", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.3415", "cds_effect": "6639C>A", "depth": "779", "equivocal": "false", "functional_effect": "missense", "gene": "ROS1", "percent_reads": "34.15", "position": "chr6:117622231", "protein_effect": "D2213E", "status": "unknown", "strand": "_", "transcript": "NM_002944", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.3167", "cds_effect": "251G>A", "depth": "884", "equivocal": "false", "functional_effect": "missense", "gene": "GABRA6", "percent_reads": "31.67", "position": "chr5:161115980", "protein_effect": "R84H", "status": "unknown", "strand": "+", "transcript": "NM_000811", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.1071", "cds_effect": "1808T>A", "depth": "1242", "equivocal": "false", "functional_effect": "missense", "gene": "REL", "percent_reads": "10.71", "position": "chr2:61149618", "protein_effect": "M603K", "status": "unknown", "strand": "+", "transcript": "NM_002908", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.1538", "cds_effect": "1470_1471GA>TT", "depth": "1326", "equivocal": "false", "functional_effect": "nonsense", "gene": "WT1", "percent_reads": "15.38", "position": "chr11:32410687", "protein_effect": "Q490_K491>H*", "status": "likely", "strand": "_", "transcript": "NM_024426", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.648", "cds_effect": "7522G>A", "depth": "7866", "equivocal": "false", "functional_effect": "missense", "gene": "BRCA2", "percent_reads": "64.8", "position": "chr13:32930651", "protein_effect": "G2508S", "status": "unknown", "strand": "+", "transcript": "NM_000059", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"allele_fraction": "0.3308", "cds_effect": "817C>T", "depth": "6941", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "33.08", "position": "chr17:7577121", "protein_effect": "R273C", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "23", "equivocal": "false", "gene": "NFKBIA", "number_of_exons": "6 of 6", "position": "chr14:35871177_35873850", "ratio": "3.95", "status": "known", "type": "amplification"}, {"copy_number": "7", "equivocal": "true", "gene": "TNFRSF14", "number_of_exons": "8 of 8", "position": "chr1:2488073_2494714", "ratio": "1.6", "status": "unknown", "type": "amplification"}, {"copy_number": "11", "equivocal": "false", "gene": "RAD52", "number_of_exons": "11 of 11", "position": "chr12:1022522_1042247", "ratio": "2.4", "status": "unknown", "type": "amplification"}, {"copy_number": "16", "equivocal": "false", "gene": "SGK1", "number_of_exons": "17 of 17", "position": "chr6:134491405_134638628", "ratio": "2.85", "status": "unknown", "type": "amplification"}, {"copy_number": "9", "equivocal": "false", "gene": "CD22", "number_of_exons": "14 of 14", "position": "chr19:35822895_35837600", "ratio": "2.08", "status": "unknown", "type": "amplification"}, {"copy_number": "7", "equivocal": "true", "gene": "CBFB", "number_of_exons": "6 of 6", "position": "chr16:67063284_67132711", "ratio": "1.7", "status": "unknown", "type": "amplification"}, {"copy_number": "11", "equivocal": "false", "gene": "KDM5A", "number_of_exons": "28 of 28", "position": "chr12:394621_498257", "ratio": "2.16", "status": "known", "type": "amplification"}, {"copy_number": "20", "equivocal": "false", "gene": "CCND2", "number_of_exons": "5 of 5", "position": "chr12:4383206_4409175", "ratio": "3.99", "status": "known", "type": "amplification"}]}, "rearrangements": {"rearrangement": {"allele_fraction": "0.1305", "description": "NOTCH3(NM_000435) rearrangement exon 6", "equivocal": "false", "in_frame": "unknown", "other_gene": "N/A", "percent_reads": "13.05", "pos1": "chr19:15302347", "pos2": "chr19:15269878", "status": "likely", "supporting_read_pairs": "249", "targeted_gene": "NOTCH3", "type": "truncation", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "3.79", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": [{"organism": "HHV_4", "reads_per_million": "41", "status": "unknown", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"organism": "HPV_16", "reads_per_million": "32", "status": "unknown", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}, {"organism": "HHV_8", "reads_per_million": "18", "status": "unknown", "dna_evidence": {"sample": "SQ_US1548766.01_1"}}]}}}}}